contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-pharma-signs-development-agreement-with-a-cosmetics-company

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Coegin Pharma

Coegin Pharma has signed a Joint Development Agreement (JDA) with a cosmetics company already marketing several consumer brands. The purpose of the JDA is to jointly progress with the next phase...

<div class="bequoted-body">Coegin Pharma has signed a Joint Development Agreement (JDA) with a cosmetics company already marketing several consumer brands. The purpose of the JDA is to jointly progress with the next phase of R&amp;D activities for the unique skin pigmentation peptide NPP-4. This agreement lays the foundation for a potential commercialisation agreement in the future.The JDA outlines that Coegin Pharma will provide the necessary NPP-4 testing materials for the upcoming phase of R&amp;D activities, while the development partner will take care of the evaluation of NPP-4. This collaboration is a key step towards a potential licensing agreement for NPP-4, contingent upon positive results from the R&amp;D activities and successful negotiations of commercial terms."We are very pleased having this JDA in place with a strong partner. This also allows us to maintain our focus on the commercialisation of our hair growth project, FOL005," says Jens Eriksson, CEO of Coegin Pharma.For further information, please contact: Jens Eriksson, CEO Email: <a rel="noopener" href="mailto:info@coeginpharma.com">info@coeginpharma.com</a> Phone: +46 72 221 24 21&nbsp;This information is information that Coegin Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 08:20 CET on 12 September 2024.This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.About Coegin Pharma Coegin&nbsp;Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia.&nbsp;Coegin&nbsp;is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.&nbsp;Coegin&nbsp;Pharma's shares are listed on&nbsp;NGM&nbsp;Nordic SME and Börse Stuttgart, and the company have a registered office in Lund, Sweden.&nbsp;For more information, please visit: <a href="http://www.coeginpharma.com/en">coeginpharma.com/en</a></div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/177b4727-a461-4991-bc7c-ebe4b658ad0d/240912-Pressrelease.pdf">240912-Pressrelease.pdf</a> </div>

Coegin Pharma signs development agreement with a cosmetics company

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

EKP:n korkopäätös: Tulkoon joulu (..ja talousoptimismi)

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn

USA:n työllisyysluvut: Taapertaen kohti vuoden loppua